Personalized Partnering: Drug, Dx Firms Should Team, Not Necessarily Merge
This article was originally published in The Gray Sheet
Executive Summary
Industry leaders disagree on whether collaborations or mergers are the best structure for effective drug/diagnostic collaborationsYou may also be interested in...
Companion Diagnostics Spark Pharma Deals, But Still Mostly For Cancer
Companion Diagnostics Spark Pharma Deals, But Still Mostly For Cancer
FDA Diagnostics Office Seeks Bigger Role In Personalized Medicine
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: